DrugBank 5.0 is a major update to the DrugBank database, released in 2018. This version represents the most significant upgrade to the database in over a decade, with a substantial increase in data content. The number of approved drugs has increased from 1836 to 2358, and the number of investigational drugs has grown from 1219 to 4501. The database now includes extensive information on drug-drug interactions, drug metabolism, pharmacogenomics, and pharmacometabolomics. New data fields have been added, including information on drug effects on metabolite, gene, and protein levels, as well as data on drug clinical trials and repurposing. The database also includes new spectral data, such as NMR and MS spectra, and has improved tools for viewing and searching these spectra. The DrugBank interface has been enhanced to support mobile devices and to improve search functionality. Additionally, a new model for data updating and distribution has been introduced, involving a public-private partnership with OMx Personal Health Analytics Inc. This partnership aims to ensure the sustainability and continued relevance of DrugBank for future research and development. The database now contains a wide range of data that can be used for pharmacogenomics, pharmacoproteomics, pharmacotranscriptomics, pharmacometabolomics, pharmacokinetics, pharmacodynamics, and drug design. The database is freely accessible and downloadable, with new datasets released under an unrestricted license. Overall, DrugBank 5.0 provides a comprehensive and up-to-date resource for drug research and development.DrugBank 5.0 is a major update to the DrugBank database, released in 2018. This version represents the most significant upgrade to the database in over a decade, with a substantial increase in data content. The number of approved drugs has increased from 1836 to 2358, and the number of investigational drugs has grown from 1219 to 4501. The database now includes extensive information on drug-drug interactions, drug metabolism, pharmacogenomics, and pharmacometabolomics. New data fields have been added, including information on drug effects on metabolite, gene, and protein levels, as well as data on drug clinical trials and repurposing. The database also includes new spectral data, such as NMR and MS spectra, and has improved tools for viewing and searching these spectra. The DrugBank interface has been enhanced to support mobile devices and to improve search functionality. Additionally, a new model for data updating and distribution has been introduced, involving a public-private partnership with OMx Personal Health Analytics Inc. This partnership aims to ensure the sustainability and continued relevance of DrugBank for future research and development. The database now contains a wide range of data that can be used for pharmacogenomics, pharmacoproteomics, pharmacotranscriptomics, pharmacometabolomics, pharmacokinetics, pharmacodynamics, and drug design. The database is freely accessible and downloadable, with new datasets released under an unrestricted license. Overall, DrugBank 5.0 provides a comprehensive and up-to-date resource for drug research and development.